Proteostasis Regulators Restore Function of Epilepsy-Associated GABAA Receptors

Xiao-Jing Di,Ya-Juan Wang,Edmund Cotter,Meng Wang,Angela L Whittsette,Dong-Yun Han,Panjamaporn Sangwung,Renae Brown,Joseph W Lynch,Angelo Keramidas,Ting-Wei Mu
DOI: https://doi.org/10.1016/j.chembiol.2020.08.012
2021-01-21
Abstract:Proteostasis deficiency in mutated ion channels leads to a variety of ion channel diseases that are caused by excessive endoplasmic reticulum-associated degradation (ERAD) and inefficient membrane trafficking. We investigated proteostasis maintenance of γ-aminobutyric acid type A (GABAA) receptors, the primary mediators of neuronal inhibition in the mammalian central nervous system. We screened a structurally diverse, Food and Drug Administration-approved drug library and identified dinoprost (DNP) and dihydroergocristine (DHEC) as highly efficacious enhancers of surface expression of four epilepsy-causing trafficking-deficient mutant receptors. Furthermore, DNP and DHEC restore whole-cell and synaptic currents by incorporating mutated subunits into functional receptors. Mechanistic studies revealed that both drugs reduce subunit degradation by attenuating the Grp94/Hrd1/Sel1L/VCP-mediated ERAD pathway and enhance the subunit folding by promoting subunit interactions with major GABAA receptors-interacting chaperones, BiP and calnexin. In summary, we report that DNP and DHEC remodel the endoplasmic reticulum proteostasis network to restore the functional surface expression of mutant GABAA receptors.
What problem does this paper attempt to address?